Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
3.
J Mater Sci Mater Med ; 27(4): 80, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26936366

RESUMO

Taking into account the influence of Si in osteoblast cell proliferation, a series of sol-gel derived silicon based coating was prepared by controlling the process parameters and varying the different Si-alkoxide precursors molar rate in order to obtain materials able to release Si compounds. For this purpose, methyltrimethoxysilane (MTMOS) and tetraethyl orthosilicate (TEOS) were hydrolysed together and the sol obtained was used to dip-coat the different substrates. The silicon release ability of the coatings was tested finding that it was dependent on the TEOS precursor content, reaching a Si amount value around ninefolds higher for coatings with TEOS than for the pure MTMOS material. To test the effect of this released Si, the in vitro performance of developed coatings was tested with human adipose mesenchymal stem cells finding a significantly higher proliferation and mineralization on the coating with the higher TEOS content. For in vivo evaluation of the biocompatibility, coated implants were placed in the tibia of the rabbit and a histological analysis was performed. The evaluation of parameters such as the bone marrow state, the presence of giant cells and the fibrous capsule proved the biocompatibility of the developed coatings. Furthermore, coated implants seemed to produce a qualitatively higher osteoblastic activity and a higher number of bone spicules than the control (uncoated commercial SLA titanium dental implant).


Assuntos
Implantes Dentários , Silício/química , Animais , Materiais Biocompatíveis , Desenvolvimento Ósseo , Medula Óssea , Teste de Materiais , Coelhos
4.
J Mater Sci Mater Med ; 24(6): 1491-9, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23475116

RESUMO

Surface engineering of biomaterials could promote the osseointegration of implants. In this work, two types of hybrid sol-gel materials were developed to stimulate cell attachment, proliferation and differentiation of osteogenic cells. One type was synthesised from vinyl triethoxysilane (VTES) and tetraethyl-orthosilicate (TEOS) at different molar ratios, while the other from VTES and hydroxyapatite particles (HAp). Hybrid materials were systematically investigated using nuclear magnetic resonance, Fourier transform infrared spectroscopy and contact angle metrology. The biocompatibility and osseoinduction of the coatings were evaluated by measuring mesenchymal stem cell proliferation using MTT assays and analysing the mineralised extracellular matrix production by quantifying calcium-rich deposits. The results highlighted the versatility of these coatings in obtaining different properties by changing the molar ratio of the VTES:TEOS precursors. Thus, mineralisation was stimulated by increasing TEOS content, while the addition of HAp improved cell proliferation but worsened mineralisation.


Assuntos
Durapatita/química , Células-Tronco Mesenquimais/citologia , Osteoblastos/citologia , Silanos/química , Engenharia Tecidual/métodos , Materiais Biocompatíveis/síntese química , Adesão Celular/fisiologia , Diferenciação Celular , Proliferação de Células , Células Cultivadas , Humanos , Teste de Materiais , Células-Tronco Mesenquimais/fisiologia , Osteoblastos/fisiologia , Osteogênese/fisiologia , Transição de Fase
5.
Med. intensiva (Madr., Ed. impr.) ; 35(supl.1): 48-52, nov. 2011.
Artigo em Espanhol | IBECS | ID: ibc-136010

RESUMO

La hiperglucemia es una de las alteraciones metabólicas predominantes en los pacientes críticos y se asocia con un aumento de la morbimortalidad. Por ello, es necesario realizar un control efectivo y a su vez seguro de la glucemia, esto es, mantener la normoglucemia en un rango que evite el riesgo de desarrollar hipoglucemia, por un lado, y las cifras elevadas de glucemia, por otro. Para conseguirlo, en la mayoría de los casos es necesario el tratamiento con insulina evitando protocolos dirigidos a conseguir cifras estrictas de glucemias. Con el fin de prevenir la hiperglucemia y sus complicaciones asociadas, el aporte energético debe adecuarse a los requerimientos de los pacientes, evitando la sobrenutrición y el aporte excesivo de glucosa. El aporte proteico se ajustará al nivel de estrés metabólico. Siempre que el enfermo requiera nutrición artificial y no esté contraindicada debe emplearse la vía enteral, ya que la nutrición parenteral se asocia a mayor frecuencia de hiperglucemia y mayores necesidades de insulina. La administración de la nutrición enteral debe ser precoz, preferiblemente dentro de las primeras 24 h de ingreso en UCI, tras la estabilización hemodinámica. Las dietas específicas para hiperglucemia que contienen hidratos de carbono de bajo índice glucémico, fibra y ricas en ácidos grasos monoinsaturados podrían conseguir un mejor control glucémico con menores necesidades de insulina (AU)


Hyperglycemia is one of the main metabolic disturbances in critically-ill patients and is associated with increased morbidity and mortality. Consequently, blood glucose levels must be safely and effectively controlled, that is, maintained within a normal range, avoiding hypoglycemia on the one hand and elevated glucose concentrations on the other. To accomplish this aim, insulin is often required, avoiding protocols designed to achieve tight glycemic control. To prevent hyperglycemia and its associated complications, energy intake should be adjusted to patients’ requirements, avoiding over nutrition and excessive glucose intake. Protein intake should be adjusted to the degree of metabolic stress. Whenever patients require artificial feeding, the enteral route , if not contraindicated, should be used since parenteral nutrition is associated with a higher frequency of hyperglycemia and greater insulin requirements. Enteral nutrition should be administered early, preferably within the first 24 hours of admission to the intensive care unit, after hemodynamic stabilization. Specific diets for hyperglycemia, containing low glycemic index carbohydrates and fibre and enriched with monounsaturated fatty acids, can achieve good glycemic control with lower insulin requirements (AU)


Assuntos
Humanos , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/etiologia , Diabetes Mellitus/terapia , Nutrição Enteral/métodos , Nutrição Enteral/normas , Hiperglicemia/tratamento farmacológico , Hiperglicemia/etiologia , Hiperglicemia/prevenção & controle , Hiperglicemia/terapia , Cuidados Críticos/métodos , Glicemia/análise , Ensaios Clínicos como Assunto , Estado Terminal/terapia , Carboidratos da Dieta/administração & dosagem , Fibras na Dieta/administração & dosagem , Proteínas na Dieta/administração & dosagem , Ingestão de Energia , Metabolismo Energético , Ácidos Graxos Monoinsaturados/administração & dosagem , Glutamina/administração & dosagem , Glutamina/uso terapêutico , Insulina/uso terapêutico , Resistência à Insulina , Estudos Multicêntricos como Assunto , Necessidades Nutricionais , Hipernutrição/prevenção & controle , Espanha , Sociedades Médicas/normas , Sociedades Científicas/normas , Nutrição Parenteral/métodos
6.
Nutr. hosp ; 26(supl.2): 46-49, nov. 2011.
Artigo em Inglês | IBECS | ID: ibc-104840

RESUMO

Hyperglycemia is one of the main metabolic disturbances in critically-ill patients and is associated within creased morbidity and mortality. Consequently, blood glucose levels must be safely and effectively controlled, that is, maintained within a normal range, avoiding hypoglycemia on the one hand and elevated glucose concentrations on the other. To accomplish this aim, insulin is often required, avoiding protocols designed to achieve tight glycemic control.To prevent hyperglycemia and its associated complications, energy intake should be adjusted to patients’ requirements, avoiding over nutrition and excessive glucose intake. Protein intake should be adjusted to the degree of metabolic stress. Whenever patients require artificial feeding, the enteral route , if not contraindicated, should be used since parenteral nutrition is associated with a higher frequency of hyperglycemia and greater insulin requirements. Enteral nutrition should be administered early, preferably within the first 24 hours of admission to the intensive care unit, after hemodynamic stabilization. Specific diets for hyperglycemia, containing low glycemic index carbohydrates and fibre and enriched with monounsaturated fatty acids, can achieve good glycemic control with lower insulin requirements (AU)


La hiperglucemia es una de las alteraciones metabólicas predominantes en los pacientes críticos y se asocia con un aumento de la morbimortalidad. por ello, es necesario realizar un control efectivo y a su vez seguro de la glucemia, esto es, mantener la normoglucemia en un rango que evite el riesgo de desarrollar hipoglucemia, por un lado, y las cifras elevadas de glucemia, por otro. Para conseguirlo, en la mayoría de los casos es necesario el tratamiento con insulina evitando protocolos dirigidos a conseguir cifras estrictas de glucemias. Con el fin de prevenir la hiperglucemia y sus complicaciones asociadas, el aporte energético debe adecuarse al os requerimientos de los pacientes, evitando la sobre nutrición y el aporte excesivo de glucosa. El aporte proteicos e ajustará al nivel de estrés metabólico. Siempre que el enfermo requiera nutrición artificial y no esté contraindicada debe emplearse la vía enteral, ya que la nutrición parenteral se asocia a mayor frecuencia de hiperglucemia y mayores necesidades de insulina. La administración de la nutrición enteral debe ser precoz, preferiblemente dentro de las primeras 24 h de ingreso en UCI, tras la estabilización hemodinámica. Las dietas específicas para hiperglucemia que contienen hidratos de carbono de bajo índice glucémico, fibra y ricas en ácidos grasos monoinsaturados podrían conseguir un mejor control glucémico con menores necesidades de insulina (AU)


Assuntos
Humanos , Hiperglicemia/dietoterapia , Diabetes Mellitus/dietoterapia , Dieta para Diabéticos/métodos , Estado Terminal/terapia , Apoio Nutricional/métodos , Prática Clínica Baseada em Evidências/métodos , Padrões de Prática Médica
7.
Med Intensiva ; 35 Suppl 1: 48-52, 2011 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-22309753

RESUMO

Hyperglycemia is one of the main metabolic disturbances in critically-ill patients and is associated with increased morbidity and mortality. Consequently, blood glucose levels must be safely and effectively controlled, that is, maintained within a normal range, avoiding hypoglycemia on the one hand and elevated glucose concentrations on the other. To accomplish this aim, insulin is often required, avoiding protocols designed to achieve tight glycemic control. To prevent hyperglycemia and its associated complications, energy intake should be adjusted to patients' requirements, avoiding overnutrition and excessive glucose intake. Protein intake should be adjusted to the degree of metabolic stress. Whenever patients require artificial feeding, the enteral route, if not contraindicated, should be used since parenteral nutrition is associated with a higher frequency of hyperglycemia and greater insulin requirements. Enteral nutrition should be administered early, preferably within the first 24 hours of admission to the intensive care unit, after hemodynamic stabilization. Specific diets for hyperglycemia, containing low glycemic index carbohydrates and fibre and enriched with monounsaturated fatty acids, can achieve good glycemic control with lower insulin requirements.


Assuntos
Cuidados Críticos , Diabetes Mellitus/terapia , Nutrição Enteral/normas , Hiperglicemia/terapia , Nutrição Parenteral/normas , Sociedades Médicas/normas , Sociedades Científicas/normas , Glicemia/análise , Ensaios Clínicos como Assunto , Cuidados Críticos/métodos , Estado Terminal/terapia , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/etiologia , Carboidratos da Dieta/administração & dosagem , Fibras na Dieta/administração & dosagem , Proteínas na Dieta/administração & dosagem , Ingestão de Energia , Metabolismo Energético , Nutrição Enteral/métodos , Ácidos Graxos Monoinsaturados/administração & dosagem , Glutamina/administração & dosagem , Glutamina/uso terapêutico , Humanos , Hiperglicemia/tratamento farmacológico , Hiperglicemia/etiologia , Hiperglicemia/prevenção & controle , Insulina/uso terapêutico , Resistência à Insulina , Estudos Multicêntricos como Assunto , Necessidades Nutricionais , Hipernutrição/prevenção & controle , Nutrição Parenteral/métodos , Espanha
8.
Nutr Hosp ; 26 Suppl 2: 46-9, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22411519

RESUMO

Hyperglycemia is one of the main metabolic disturbances in critically-ill patients and is associated with increased morbidity and mortality. Consequently, blood glucose levels must be safely and effectively controlled, that is, maintained within a normal range, avoiding hypoglycemia on the one hand and elevated glucose concentrations on the other. To accomplish this aim, insulin is often required, avoiding protocols designed to achieve tight glycemic control. To prevent hyperglycemia and its associated complications, energy intake should be adjusted to patients' requirements, avoiding overnutrition and excessive glucose intake. Protein intake should be adjusted to the degree of metabolic stress. Whenever patients require artificial feeding, the enteral route, if not contraindicated, should be used since parenteral nutrition is associated with a higher frequency of hyperglycemia and greater insulin requirements. Enteral nutrition should be administered early, preferably within the first 24 hours of admission to the intensive care unit, after hemodynamic stabilization. Specific diets for hyperglycemia, containing low glycemic index carbohydrates and fibre and enriched with monounsaturated fatty acids, can achieve good glycemic control with lower insulin requirements.


Assuntos
Estado Terminal/terapia , Diabetes Mellitus/terapia , Hiperglicemia/terapia , Apoio Nutricional/métodos , Glicemia/metabolismo , Consenso , Fibras na Dieta/administração & dosagem , Proteínas na Dieta/administração & dosagem , Ácido Eicosapentaenoico/administração & dosagem , Ingestão de Energia , Nutrição Enteral , Glutamina/administração & dosagem , Índice Glicêmico , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/uso terapêutico , Insulina/administração & dosagem , Insulina/uso terapêutico , Nutrição Parenteral/métodos , Oligoelementos/administração & dosagem , Vitaminas/administração & dosagem , Ácido gama-Linolênico/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...